{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Descriptive statistics including mean, median, standard deviation, and range will be calculated for baseline for patients with PTC, TG and TG antibody, and presence of BRAF mutation or RET/PTC rearrangement.","groups":[{"description":"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28\n\npharmacological study: Optional correlative studies\n\nlaboratory biomarker analysis: Optional correlative studies","id":"OG000","title":"Group 1 Relapsed/Refractory Rhabdomyosarcoma"},{"description":"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28\n\npharmacological study: Optional correlative studies\n\nlaboratory biomarker analysis: Optional correlative studies","id":"OG001","title":"Group 2 Relapsed/Refractory Wilms Tumor"}],"populationDescription":"No patients were enrolled with PTC (papillary thyroid carcinoma) so there are no patients who can contribute to this outcome measure.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Presence of BRAF Mutation or RET/PTC Rearrangement","type":"SECONDARY"}